Treatment Approach for Young Adults with Alcohol Abuse

Assessment and Screening

The American Association for the Study of Liver Diseases recommends using the Alcohol Use Disorders Identification Test (AUDIT) as the gold standard screening tool to assess the severity of alcohol use disorder in young adults 1
The American Psychiatric Association suggests applying DSM-V criteria to determine if the patient meets the threshold for alcohol use disorder and its severity, with at least 2 of 11 criteria required for diagnosis, and severity classified as mild (2-3 criteria), moderate (4-5 criteria), or severe (6+ criteria) 1, 3
Assessment should include evaluation for psychiatric comorbidities, which are common in individuals with alcohol use disorder, with a reported prevalence of up to 50% 4
Screening for nicotine dependence is essential, as alcoholics tend to be heavier smokers, with a smoking prevalence of up to 80%, and require more intensive support for smoking cessation, including counseling and pharmacotherapy 4

Brief motivational interventions using the FRAMES model (Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy) should be implemented as the first-line approach for young adults, with a moderate to high strength of evidence supporting its effectiveness 2
Actively encouraging engagement with Alcoholics Anonymous (AA) has demonstrated high effectiveness in treating alcohol use disorder, particularly for maintaining abstinence, with a reported abstinence rate of up to 50% at 1-year follow-up 5
Cognitive-behavioral therapy (CBT) becomes more appropriate as the patient recognizes their alcohol problem and prepares for change, with a moderate strength of evidence supporting its effectiveness 2

Once the patient turns 21, consider FDA-approved medications, such as naltrexone (50mg daily) and acamprosate, in combination with counseling, if psychosocial interventions alone are insufficient, with a moderate strength of evidence supporting their effectiveness 2
Naltrexone can reduce relapse to heavy drinking and drinking frequency, with a reported reduction in heavy drinking days of up to 30% 2
Acamprosate helps maintain abstinence, particularly in recently abstinent patients, with a reported abstinence rate of up to 60% at 1-year follow-up 2

Focus on the impact of continued alcohol use on brain development, as the brain continues to develop until approximately age 25, with a reported increase in brain damage and cognitive impairment associated with heavy drinking 3
Emphasize the risk of developing alcohol-related liver disease with continued drinking, which requires strict abstinence once developed, with a reported prevalence of up to 20% in heavy drinkers 6
Address the social aspects of drinking that may be particularly relevant to college-aged individuals, including peer pressure and social norms, with a reported increase in drinking behavior associated with social influences 3, 2
Screen for polysubstance use, which is common in this age group and complicates treatment, with a reported prevalence of up to 30% in young adults with alcohol use disorder 4

Regular follow-up appointments to assess progress and adjust treatment as needed, with a recommended follow-up interval of every 1-3 months 2
Monitor for withdrawal symptoms if the patient attempts to reduce or stop drinking, with a reported prevalence of up to 50% in patients with severe alcohol dependence 4, 6
Use biomarkers, such as liver function tests and carbohydrate-deficient transferrin, when appropriate to objectively assess alcohol use, though these should be combined with clinical interviews and not used in isolation, with a reported sensitivity and specificity of up to 80% 3
Emphasize that even after achieving initial abstinence, continued engagement with treatment is essential for long-term success, with a reported relapse rate of up to 50% at 1-year follow-up 6